Evolus - EOLS STOCK NEWS

Evolus, Inc. (NASDAQ: EOLS) has appointed Jessica Novak as Senior Vice President of Human Resources to enhance its talent management strategy. Novak brings over 20 years of experience from various industries, including consulting and biotech. David Moatazedi, President and CEO, emphasized that her expertise aligns with Evolus' mission to improve the beauty experience. Evolus is known for its aesthetic product, Jeuveau®, which is FDA-approved and aims to innovate within the aesthetics market.

Evolus, Inc. (NASDAQ: EOLS) has announced it will report its Q3 2021 financial results and provide a business update on November 2, 2021, before U.S. market opening. Management will hold a conference call at 9:00 a.m. ET to discuss these results, followed by a Q&A session. Interested parties can participate by calling (877) 407-6184 for U.S. callers or (201) 389-0877 for international callers, or via a live webcast on Evolus' Investor Relations page. A replay of the call will be available post-event.

Evolus, Inc. (NASDAQ: EOLS) announces participation in two investment conferences this September. The first event is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, available on-demand from 7:00am ET. The second is the Cantor 2021 Virtual Global Healthcare Conference on September 28 at 3:20pm ET. Both webcasts will be accessible on Evolus' investor relations website for 90 days post-presentation. Evolus is known for its innovative beauty products, including Jeuveau®, the first neurotoxin dedicated to aesthetics, approved by the FDA in 2019.

Evolus reported a remarkable 235% year-over-year increase in net revenue, reaching $26.1 million for Q2 2021, significantly exceeding its annualized revenue run rate goal of $100 million.

The company ended the quarter with a strong cash position of $131.7 million and is on track for a European launch in early 2022, targeting a potential $470 million market. Key drivers included increased Jeuveau® sales and a growing customer base, with over 6,000 purchasing accounts and 200,000 registered in its loyalty program.

Evolus, a performance beauty company, will announce its second quarter 2021 financial results on August 4, 2021, after U.S. market close. A conference call will follow at 4:30 p.m. ET, including a Q&A session. Interested participants can join the call by dialing (877) 407-6184 (U.S.) or (201) 389-0877 (international) and via their Investor Relations webpage. Evolus is known for its FDA-approved aesthetic neurotoxin, Jeuveau®, which aims to transform the beauty market. For more information, visit www.evolus.com.

Evolus, Inc. (Nasdaq: EOLS) has appointed David K. Erickson as Vice President of Investor Relations, effective immediately. With over 25 years of experience in investor relations and the healthcare sector, Erickson is expected to enhance the company's strategic investor communications. His prior roles include positions at Establishment Labs Holdings and Edwards Lifesciences. Evolus aims to expand its global presence, including a European launch anticipated in early 2022, which will further benefit from Erickson's industry connections and expertise.

Evolus, Inc. (Nasdaq: EOLS) announced a peer-reviewed article in Dermatologic Surgery highlighting prabotulinumtoxinA (Jeuveau^®)'s efficacy for treating glabellar lines in patients with Skin of Color (SOC). The study compared outcomes in 492 patients and found responder rates were slightly lower for SOC patients. Notably, the headache was the most common adverse event, affecting 12.1% of SOC patients. With growing demand from SOC patients, understanding the effectiveness and safety differences between SOC and non-SOC populations becomes crucial for dermatologists.

Evolus, Inc. (Nasdaq: EOLS) has appointed Dan Stewart as Vice President and General Manager of its International business. With over 20 years of experience in medical aesthetics, Stewart is expected to lead Evolus' global expansion, beginning with the European launch of Nuceiva™ in early 2022. The Chief Marketing Officer praised Stewart's successful track record. Evolus is known for its customer-centric approach and innovative products, including Jeuveau®, a unique neurotoxin approved for aesthetics.

Evolus, Inc. (Nasdaq: EOLS) reported Q1 2021 net revenues of $12.2 million, a 16% increase from the previous year, aided by the resolution of an International Trade Commission (ITC) case. The company's pro forma cash position stood at $140 million as of March 31, 2021. The U.S. Jeuveau® business is on track for a $100 million annual revenue run rate in Q2 2021. Moreover, operating expenses decreased by 25.7% year-over-year, while gross margins are expected to stabilize post-September 2022.